Rocket Pharmaceuticals, Inc.
RCKT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001281895
In the last 90 days, Rocket Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 7 sales; 180 institutions reported holding it in 13F filings for Q2 2026, worth $340.9M in total; Maverick Capital is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Rocket Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 7 filings
- 4 insiders, $432.5K in total
- Insiders trading
- 4
- Net value
- −$432.5K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Rocket Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Wilson Martin | General Counsel | 598,489 | Sep 15, 2026 | 10 |
| Shah Gaurav | CEO | 1,056,594 | Aug 20, 2026 | 9 |
| Stevens Christopher James | Chief Operating Officer | 505,784 | Aug 13, 2026 | 3 |
| Chaudhuri Sarbani | See Remarks | 262,809 | Aug 13, 2026 | 3 |
| Southwell David P | Director | 204,522 | Aug 5, 2026 | 2 |
| Wong Roderick | Director, 10% Owner | 75,499 | Jul 6, 2026 | 1 |
| Fong Peter | Director | 76,195 | Jul 6, 2026 | 2 |
| Dolsten Mikael | Director | 67,082 | Jul 6, 2026 | 1 |
| Malik Fady Ibraham | Director | 52,862 | Jul 6, 2026 | 1 |
| Boess Carsten | Director | 52,862 | Jul 6, 2026 | 1 |
| Militello John | See Remarks | 89,780 | May 28, 2026 | 8 |
| Rizvi Syed Ali-aamir | Chief Medical Officer | 407,874 | Feb 13, 2026 | 2 |
| Bjork Elisabeth | Director | 50,000 | Jan 6, 2026 | 1 |
| Schwartz Jonathan David | See Remarks | 299,064 | Nov 20, 2025 | 1 |
| RTW Investments, LP | Director, 10% Owner, Other: See remarks | 18,188,457Indirect | Sep 23, 2025 | 0 |
| Granadillo Pedro P | Director | 54,734 | Jul 18, 2025 | 0 |
| Makker Gotham | Director | 415,346Indirect | Jul 18, 2025 | 0 |
| Pratumsuwan Piratip | Director | 30,000 | Jul 18, 2025 | 0 |
| Ondrey Aaron | Chief Financial Officer | 128,173 | Jul 8, 2025 | 0 |
| Patel Kinnari | See Remarks | 441,927 | May 22, 2025 | 0 |
| White Mark Andrew | See Remarks | 69,140 | Nov 4, 2024 | 0 |
| Yalamanchi Naveen | Director | 16,272,635Indirect | Jun 20, 2024 | 0 |
| Woods Keith | Director | – | Jun 20, 2024 | 0 |
| Garcia-Parada Carlos | Chief Financial Officer | – | Feb 16, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 (view filing)8:27 PM ET | Sep 11 | 4 days | Wilson MartinGeneral Counsel | SSale | −75.4K | $3.40 | −$256.5K | −11.2%598.5K after |